Patients with HIV-1 immune-related
thrombocytopenia (HIV-1-ITP) have a unique Ab against platelet GPIIIa49-66 capable of inducing oxidative platelet fragmentation in the absence of
complement. HIV-1-seropositive drug abusers are more prone to develop
immune thrombocytopenia than non-drug abusers and have a higher
coinfection with hepatitis C virus (HCV) than non-drug abusers (90% vs 30%). Molecular mimicry was sought by screening a phage
peptide library with anti-GPIIIa49-66 antibody as bait for
peptides sharing homology sequences with HCV. Several phage
peptide clones had 70% homology with HCV
protein. Sera from dually infected thrombocytopenic patients with HCV and HIV-
ITP reacted strongly with 4 nonconserved
peptides from HCV core envelope 1. Reactivity correlated inversely with platelet count (r(2) = 0.7, P < .01). Ab raised against
peptide PHC09 in
GPIIIa(-/-) mice induced
thrombocytopenia in wild-type mice. Affinity-purified
IgG against PHC09 induced oxidative platelet fragmentation in vitro. Drug abusers dually infected with HCV and HIV-1 had a greater incidence and severity of
thrombocytopenia as well as titer of anti-GPIIIa49-66/PHC09 Ab. NZB/W F1 mice injected with recombinant core envelope 1 developed Ab versus PHC09 and significantly decreased their platelet count (P < .001). Thus, HCV core envelope 1 can induce
thrombocytopenia by molecular mimicry with GPIIIa49-66.